Renaissance Technologies’s Centessa Pharmaceuticals CNTA Stock Holding History

Renaissance Technologies’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.35M	Sell	185,000 -94,300	-34%	-$2.41M	0.01%	1150
2025 Q4	$6.99M	Buy	279,300 +114,700	+70%	+$2.91M	0.01%	1110
2025 Q3	$3.99M	Sell	164,600 -220,300	-57%	-$3.92M	0.01%	1629
2025 Q2	$5.06M	Buy	384,900 +206,900	+116%	+$2.62M	0.01%	1522
2025 Q1	$2.56M	Sell	178,000 -600	-0.3%	-$9.82K	﹤0.01%	1847
2024 Q4	$2.99M	Sell	178,600 -31,000	-15%	-$514K	﹤0.01%	1780
2024 Q3	$3.35M	Buy	209,600 +35,900	+21%	+$440K	0.01%	1699
2024 Q2	$1.57M	Sell	173,700 -45,100	-21%	-$428K	﹤0.01%	2028
2024 Q1	$2.47M	Buy	218,800 +33,200	+18%	+$314K	﹤0.01%	1891
2023 Q4	$1.48M	Buy	185,600 +132,500	+250%	+$888K	﹤0.01%	2147
2023 Q3	$344K	Buy	53,100 +18,800	+55%	+$129K	﹤0.01%	2869
2023 Q2	$212K	Buy	34,300 +18,600	+118%	+$88.2K	﹤0.01%	3281
2023 Q1	$60K	Buy	+15,700	New	+$57.4K	﹤0.01%	3616

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies's CNTA Position: Q1 2026 in Review

Renaissance Technologies reduced its Centessa Pharmaceuticals (CNTA) stake by 34% in Q1 2026, selling an estimated $2.41M and leaving 185,000 shares worth $7.35M. The position accounts for 0.01% of the portfolio, ranked #1150.

Renaissance Technologies first reported a position in CNTA in Q1 2023 and has held it in 13 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Renaissance Technologies held 185,000 shares of Centessa Pharmaceuticals worth $7.35M as of Q1 2026.
Renaissance Technologies sold 94,300 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2.41M.
Centessa Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1150 holding.
Renaissance Technologies first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.